Overview

A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach

Status:
Terminated
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
To determine whether the combination of MM-111 plus paclitaxel and trastuzumab is more effective than paclitaxel and trastuzumab alone
Phase:
Phase 2
Details
Lead Sponsor:
Merrimack Pharmaceuticals
Treatments:
Albumin-Bound Paclitaxel
Paclitaxel
Trastuzumab